Regeneron Pharmaceuticals (REGN) Receivables (2009 - 2026)

Regeneron Pharmaceuticals has reported Receivables for 18 years, with the latest figure at $6.6 billion in Q2 2026.

• On a quarterly basis, Receivables rose 17.03% year-over-year to $6.6 billion in Q2 2026; TTM through Jun 2026 was $6.6 billion, a 17.03% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, down 7.58% from the prior year.
• Receivables was $6.6 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $5.7 billion in the prior quarter.
• The five-year high for Receivables was $6.6 billion in Q2 2026, with the low at $4.8 billion in Q1 2022.
• Average Receivables over 5 years is $5.6 billion, with a median of $5.6 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Receivables declined 26.25% in 2022, then increased 17.03% in 2026.
• Over 5 years, Receivables stood at $5.3 billion in 2022, then climbed by 6.35% to $5.7 billion in 2023, then rose by 9.61% to $6.2 billion in 2024, then slipped by 7.58% to $5.7 billion in 2025, then gained by 14.36% to $6.6 billion in 2026.
• The last three Receivables figures came in at $6.6 billion (Q2 2026), $5.7 billion (Q1 2026), and $5.7 billion (Q4 2025), per Business Quant data.